Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease

Journal of Gastrointestinal and Liver Diseases

Volumn 15, Issue 3, 2006, Pages 231-235

  Ferkolj, Ivan ^a   Ihan, Alojz ^b   Markovič, Saša ^a   Večerič, Zeljka ^a   Pohar, Maja ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Crohn's disease; Flow cytometry; Inflammation; Infliximab; Lymphocytes

Indexed keywords

AZATHIOPRINE; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CIPROFLOXACIN; CORTICOSTEROID; HLA DR ANTIGEN; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENTERITIS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGICAL PARAMETERS; INTESTINE BIOPSY; INTESTINE EPITHELIUM; INTESTINE MUCOSA; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED;

EID: 33749262823     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hoffmann J C, Zeitz M. Treatment of Crohn's disease. Hepatogastroenterology 2000; 47: 90-100.
2. Panaccione R, Sandborn WJ. Medical therapy of Crohn's disease. Curr Opin Gastroenterol 2004; 20: 351-359.
3. Van Assche G, Vermeire S, Rutgeerts P. Medical treatment of inflammatory bowel diseases. Curr Opin Gastroenterol 2005; 21: 443-447.
4. Kruis W. Crohn's disease - standards of treatment 2004. Schweiz Rundsch Med Prax 2005; 94: 1595-1598.
5. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-362.
6. Plevy SE, Landers CJ, Prehn J et al. A role for TNF-α and mucosal T-helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159: 6276-6282.
7. Neuman MG. Signaling for inflammation and repair in inflammatory bowel disease. Rom J Gastroenterol 2004; 13: 309-316.
8. Papadakis KA. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep 2004; 4: 83-89.
9. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
10. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
11. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
12. Gheorghe L, Gheorghe C, Badea M et al. Infliximab for Crohn's disease in clinical practice: the experience of a single center in Romania. Rom J Gastroenterol 2003;12: 7-13.
13. Sands BE, Blank MA, Patel K, van Deventer SJ. Accent II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 912-920.
14. Bewtra M, Lichtenstein GR. Infliximab use in Crohn's disease. Expert Opin Biol Ther 2005; 5: 589-599.
15. Baert FJ, Rutgeerts PR. Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int J Colorectal Dis 1999; 14: 47-51.
16. Targan SR. Biology of inflammation in Crohn's disease: mechanisms of action of anti TNF therapy. Can J Gastroenterol 2000; 14: 13C-16C.
17. Geboes K, Rutgeerts P, Opdenakker G et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 2005; 21: 1741-1754.
18. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444.
19. Forbes A. Epidemiology, aetiology and pathogenesis. In: Clinicians' guide to inflammatory bowel disease (Forbes A, ed). London, Chapman-Hill Medical 1997: 1-44.
20. Andus T, Gross V. Etiology and pathophysiology of inflammatory bowel disease - environmental factors. Hepatogastroenterology 2000; 47: 29-43.
21. Scholmerich J. New developments in aetiological mechanisms of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003; 15: 585-586.
22. Schmidt C, Stallmach A. Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol 2005; 51: 127-145.
23. Schreiber S. Inflammatory bowel disease: immunologic concepts. Hepatogastroenterology 2000; 47: 15-28.
24. Cornillie F, Shealy D, D'Haens G et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 15: 463-473.
25. Maurice MM, Van der Graaff WL, Loew A, Breedveld FC, Van Lier RA, Verveij CL. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 2166-2173.
26. D'Haens G, Van Deventer S, Van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999; 116: 1029-1034.
27. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22-28.
28. Agnholt J, Dahlerup JF, Buntzen S, Tottrup A, Nielsen SL, Lundorf E. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Aliment Pharmacol Ther 2003; 17: 703-710.
29. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-1157.
30. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-211.
31. Di Sabatino A, Ciccocioppo R, Cinque B et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53: 70-77.
32. Shen C, Maerten P, Geboes K, Van Assche G, Rutgeerts P, Ceuppens JL. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005; 115: 250-259.